480 Biomedical Announces First Human Trial of the StanzaTM Bioresorbable Scaffold in Peripheral Artery Disease

Published: Apr 16, 2012

WATERTOWN, Mass.--(BUSINESS WIRE)--480 Biomedical announced today that it has initiated the first human trial of its groundbreaking StanzaTM self-expanding bioresorbable scaffold for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). The StanzaTM scaffold restores blood flow to the leg by propping open the diseased artery during the critical healing period, similar to conventional metal stents, but then is resorbed by the body. Observations from the first patients in the STANCE trial were reported on April 14 at the 34th Charing Cross International Symposium in London.

Back to news